You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Neural Stem Cell Extracellular Vesicle Treatment for Traumatic Brain Injury

    SBC: ARUNA BIO, INC.            Topic: NINDS

    Project Summary/AbstractTraumatic brain injury (TBI) is a universal health concern and is known as a “silent epidemic”. Each year in America, 2.53 million patients visit the emergency department after suffering a TBI of which 56,800 die and over 288,000 require hospitalization, rehabilitation programs, and long-term supportive care. Although the primary TBI event is typically acute, subsequent ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Colon cancer prevention with non-systemic PDE5 inhibitors

    SBC: Targut Biotechnologies Inc.            Topic: 102

    Approximately 50,000 people will die from colorectal cancer (CRC) in the United States this year due to the late stage at diagnosis where treatments are largely ineffective. Primary prevention of CRC is therefore very important for high-risk patients. Chemoprevention agents are needed for CRC but nothing has been approved for this purpose. Extensive preclinical and epidemiological evidence show gr ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of the UValidate platform for the profiling of topically applied chemical agents.

    SBC: AMELIA TECHNOLOGIES LLC            Topic: R

    Project Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer

    SBC: PAZ PHARMACEUTICALS LLC            Topic: NCI

    Summary Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the U.S. with a 5-year survival rate of andlt;9%. The poor prognosis is partially due to resistance to standard of care treatments including gemcitabine (Gem) and Gem+nab-paclitaxel (n-PTX). The transcription factors HIF-1α and c-MYC are at the center of the mechanisms producing Gem and n-PTX resistance ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. A Precision Medicine Tool for Optimal Personalized Treatment in Patients with Acute Myeloid Leukemia

    SBC: SANICKA, INC            Topic: NCI

    Acute myeloid leukemia (AML) is an aggressive cancer of the bone marrow and peripheral blood with poor prognosis mostly due to relapse. Despite decades of improvements in chemo-immunotherapy (CIT) and, more recently, the use of hypomethylating agent (HMAs) and addition of novel small molecule inhibitors (SMIs) to back-bone chemotherapy, AML treatment selection and dosage remains mostly empiric, wi ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Simulated Exposure Trainer (SET-VR): Implementing Targeted Experiential Training with a Virtual Patient

    SBC: VIRTUALLY BETTER INC            Topic: 104

    PROJECT SUMMARY/ABSTRACT Despite the existence of numerous, well-established evidence-based practices (EBPs) for mental disorders, it has been difficult to disseminate these practices in community settings. Exposure therapy for anxiety disorders represents one of the most glaring examples of this research-to-practice gap. Just as patients are anxious about approaching their fears, therapists are o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Feasibility study of novel hand hygiene formulations against bacterial spore infection

    SBC: CAMELLIX, LLC            Topic: NIAID

    Project Summary: Spore-forming bacterial species, such as various Bacilli and Clostridia, undergo a sporulation process under unfavorable conditions to form dormant spores. These bacterial spores have become a threat to the food industry as they can cause food spoilage and food poisoning. In addition, an opportunistic pathogen, Clostridium difficile (C. difficile), one of the five CDC- listed urge ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Imaging Bacterial Infections in Vivo: First in Man Studies

    SBC: Microbial Medical, Inc.            Topic: NIAID

    Project Summary/AbstractInfection is the major complication of virtually all medical devices. It is estimated that 2 million patients acquire a nosocomial infection in the US every year and the CDC estimates that the financial impact of these infections exceeds 5 billion dollars annually. At least half of these infections are directly associated with medical devices. Most commonly, the diagnosis o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Nasal Formulations Containing EC16 for Minimizing COVID-19-Associated Anosmia

    SBC: CAMELLIX, LLC            Topic: NIDCD

    Project Summary/Abstract SARS-CoV-2 infection is associated with high mortality and morbidity worldwide. A common sequela is anosmia, the loss of the sense of smell, which can impact the quality of life severely. This is due to the robust replication of SARS-CoV-2 in the nasal neuroepithelial cells, leading to acute or chronic olfactory dysfunction (anosmia). A significant number of patients in th ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist

    SBC: VIRTUALLY BETTER INC            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government